{"nctId":"NCT00516048","briefTitle":"An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes","startDateStruct":{"date":"2007-08"},"conditions":["Type 2 Diabetes Mellitus"],"count":58,"armGroups":[{"label":"Exenatide:Treatment-Emergent Antibody Negative","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]},{"label":"Exenatide:Treatment-Emergent Antibody Positive","type":"EXPERIMENTAL","interventionNames":["Drug: exenatide"]}],"interventions":[{"name":"exenatide","otherNames":["Byetta","AC2993","LY2148568"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes.\n* Have been exposed to exenatide for at least 3 months in previous Amylin/Lilly Studies H8O-MC-GWAO, H8O-MC-GWAP, H8O-MC-GWAT, or H8O-MC-GWBA.\n* Have interrupted exenatide treatment for a period of at least 2 months.\n* HbA1c of ≤10.5%.\n\nExclusion Criteria:\n\n* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.\n* Have previously completed or withdrawn from this study.\n* Have taken marketed exenatide (Byetta) during the interim period between studies GWAO, GWAP, GWAT, or GWBA and the current study.\n* Used drugs for weight loss (for example, Xenical® \\[orlistat\\], Meridia® \\[sibutramine\\], Acutrim® \\[phenylpropanolamine\\], Accomplia® \\[rimonabant\\], or similar over-the-counter medications) within 3 months of screening.\n* Are currently treated with any of the following excluded medications: Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.\n* Use insulin with daily dosage exceeding 1 U/kg.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Treatment-emergent Antibody Status (Maximum Titer Level Experienced)","description":"Patients who experienced specified treatment-emergent antibody status at any point during the study (grouped by maximum titer level experienced)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint","description":"Change in HbA1c from baseline (Week 0) to endpoint (Week 24) by treatment-emergent antibody status","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":"0.66"},{"groupId":"OG001","value":"8.05","spread":"1.00"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.03","spread":"0.74"},{"groupId":"OG001","value":"-0.30","spread":"0.94"},{"groupId":"OG002","value":"0","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Potentially Immune-related Treatment-emergent Adverse Events","description":"Number of patients experiencing a potentially immune-related treatment-emergent adverse event at any point during the study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0},"commonTop":["Nasopharyngitis","Influenza","Injection site pruritis","Toothache","Viral infection"]}}}